Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus LUSEDRA.
DETROL vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
5 mg orally once daily.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic